With advanced vehicle tracking, superior battery life and a brighter tail light than ever before, cyclists can ride with greater peace of mind OLATHE, Kan., Feb. 3, 2026 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced Varia™ RearVue 820 , its most innovative radar tail light that can help cyclists be more aware and visible while riding on the road.

image for news Garmin unveils Varia RearVue 820, its brightest and most powerful radar tail light for cyclists

NEW HAVEN, Conn., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has received and is aligned with advice from the U.S. Food and Drug Administration (FDA) on the LIBERTY Phase 3 clinical trial, which will assess the safety and immunologic profile of VYD2311, the company's vaccine- alternative monoclonal antibody investigational candidate for the prevention of COVID-19, versus commercially available mRNA COVID vaccines. The trial will also explore the safety and immunologic profile of VYD2311 and mRNA COVID vaccine administered simultaneously.

image for news Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

BellRing Brands Announces Leadership Transition Plan — Neutral

BRBR   GlobeNewsWire — February 03, 2026

ST. LOUIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) (the “Company”) today announced that its President and Chief Executive Officer Darcy Davenport has decided to retire from the Company, effective upon the earlier of the appointment of a new Chief Executive Officer or September 30, 2026, the end of the Company's fiscal year. Ms. Davenport will continue to serve as President and Chief Executive Officer and as a member of the Board until the effective date of the transition, after which she will serve in an advisory role to ensure a smooth transition of leadership responsibilities and …

image for news BellRing Brands Announces Leadership Transition Plan

AI sets Tesla stock's 2026 record high price — Positive

TSLA   Finbold — February 03, 2026

Artificial intelligence model ChatGPT has outlined a bullish case scenario for Tesla (NASDAQ: TSLA) shares in 2026.

image for news AI sets Tesla stock's 2026 record high price

Best Growth Stocks to Buy for February 3rd — Positive

SDVKY  TCBI  WDC   Zacks Investment Research — February 03, 2026

SDVKY, WDC and TCBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 3, 2026.

image for news Best Growth Stocks to Buy for February 3rd

Analysts say they're looking for details on the deal between Apple and Google to revamp the iPhone maker's AI products, including Siri. The deal is one of the most prominent yet for Gemini, and the scale of Apple's user base — 2.5 billion active devices — is important for Google, even without specific user data, analysts said.

image for news In Google earnings, analysts want answers on Apple's Siri-Gemini deal

Amazon is ratcheting up fast delivery and raising the stakes for rivals like Walmart — Positive

AMZN  WMT   Business Insider — February 03, 2026

Amazon sets a new delivery speed record in 2025, with over 13 billion same- or next-day deliveries worldwide. Prime members in the US received a 30% increase in fast deliveries in 2025, the company said.

image for news Amazon is ratcheting up fast delivery and raising the stakes for rivals like Walmart

Pierre Beaudoin Appointed as Strategic Advisor to Mayfair Gold — Neutral

MINE   PRNewsWire — February 03, 2026

VANCOUVER, BC, Feb. 3, 2026 /PRNewswire/ - Mayfair Gold Corp. ("Mayfair", "Mayfair Gold", or the "Company") (NYSE American: MINE) (TSXV: MFG) is pleased to announce the appointment of Pierre Beaudoin as Strategic Advisor to the Company. Mr. Beaudoin is a mineral processing professional with 40 years of international operating and project development experience.

image for news Pierre Beaudoin Appointed as Strategic Advisor to Mayfair Gold

Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough …

image for news Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

Artisan Global Value Fund Q4 2025 Portfolio Activity — Neutral

BAESF  BAESY  CMPGY  DEO  GOOGL  HLBZF  LUV  META  PYPL  SSNLF   Seeking Alpha — February 03, 2026

Artisan Global Value Fund Q4 2025 Portfolio Activity

image for news Artisan Global Value Fund Q4 2025 Portfolio Activity

J & J Snack Foods Reports Fiscal 2026 First Quarter Results — Neutral

JJSF   GlobeNewsWire — February 03, 2026

MOUNT LAUREL, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- J & J Snack Foods Corp. (Nasdaq: JJSF) today reported financial results for the first quarter ended December 27, 2025.

image for news J & J Snack Foods Reports Fiscal 2026 First Quarter Results

WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY.

image for news Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

TORONTO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) has awarded a US$6.1 million (C$8.3 million) contract to EXP Services Inc. ("EXP") to provide engineering, project management, and construction management services during the construction phase of Electra's Ontario battery materials refinery project.

image for news Electra Awards $6.1 Million Contract to EXP Services for Project Management and Engineering Support at Ontario Refinery

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing — Neutral

ANL   GlobeNewsWire — February 03, 2026

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.

image for news Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026 in New York. The X4 team will hold a fireside chat on February 12th at 12:30 p.m.

image for news X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

ST. LOUIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global proactive wellness category, today reported results for the first fiscal quarter ended December 31, 2025.

image for news BellRing Brands Reports Results for the First Quarter of Fiscal Year 2026; Narrows Fiscal Year 2026 Outlook

HP Inc. to Announce First Quarter Fiscal 2026 Earnings on Feb 24, 2026 — Neutral

HPQ   GlobeNewsWire — February 03, 2026

PALO ALTO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) will present a live audio webcast of a conference call to review financial results for the first fiscal quarter ended January 31, 2026 on Tuesday, Feb 24, 2026 at 5:00 p.m. ET / 2:00 p.m. PT.

image for news HP Inc. to Announce First Quarter Fiscal 2026 Earnings on Feb 24, 2026

Gear up for game day, Sunday, February 8, 2026, with ultimate fan experiences, beer, wings, whiskey, and more at SweetWater Brewing Co., Montauk Brewing Co., Breckenridge Brewery, Blue Point Brewing Co., 10 Barrel Brewing Co., Hop Valley Brewing Co., Terrapin Beer Co., and Atwater Brewery Gear up for game day, Sunday, February 8, 2026, with ultimate fan experiences, beer, wings, whiskey, and more at SweetWater Brewing Co., Montauk Brewing Co., Breckenridge Brewery, Blue Point Brewing Co., 10 Barrel Brewing Co., Hop Valley Brewing Co., Terrapin Beer Co., and Atwater Brewery

image for news Tilray Brands Ignites Championship Sunday: Nationwide Tap Room Events, Big Game Day Deals, and Fan Experiences Announced

Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results — Neutral

OFIX   Business Wire — February 03, 2026

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other location.

image for news Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced leadership transitions for its next phase of innovation. Travis Thompson, who began at Bicycle in April 2018 and most recently served as Bicycle's senior vice president and chief accounting officer and previously spent his career at EY in its life.

image for news Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline